The number of treatments formulated each year has increased dramatically over the last 10 years due to technological advancements within the biomedical field. However, formulation and development does not necessarily equate to launch on the market, as many treatments are deemed ineffective, inferior to those already on the market, or unsafe.  Therefore, all treatments produced by pharmaceuticals must undergo rigorous testing before being launched on the market. It would of course be premature and dangerous to immediately commence the testing of a new treatment in human subjects.  As such, scientists take to studying the effects in models, which can include

The scientific community has known for some time that different people respond differently than others to similar environments, and this is also the case with nutrition. After all, we’ve all heard a friend say that a particular diet worked wonders for them, but when we try the same program, we don’t see the same success. Wouldn’t it be great if there were a way to know whether your genetic blueprint was compatible with a particular diet or exercise regimen? Or whether you have specific sensitivities to certain foods? And what if you could understand your genetic susceptibility to stress or

WITH ANKASCIN – CLINICAL RESEARCH The key findings relevant to the use of Ankascin red yeast rice to manage blood cholesterol came from an experimental study in hamsters. Unlike other animals commonly used in research, hamsters develop many of the key characteristics of human cardiovascular disease when fed a diet that is high in fats and sugar15. The positive effects of monascin and ankaflavin in animal models led to human clinical trials to evaluate the ability of these molecules to manage blood cholesterol, blood pressure, and blood sugar. STUDY MONASCIN AND ANKAFLAVIN ACT AS NOVEL HYPOLIPIDEMIC AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL-RAISING